Literature DB >> 21184240

Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria.

Jee Min Park1, Sung Chul Won, Jae Il Shin, Hyunee Yim, Ki Soo Pai.   

Abstract

To evaluate the therapeutic role of cyclosporin A (CyA) for the treatment of Henoch-Schönlein nephritis (HSN), 29 patients (18 boys, 11 girls) with nephrotic-range proteinuria were analyzed retrospectively. Mean age was 8.6 years (range 2.0-15.5 years) at diagnosis of Henoch-Schönlein purpura (HSP). All patients had developed the nephrotic-range proteinuria at a mean interval of 4.4 months (range 0-50.7 months) after the diagnosis of HSP. Mean duration of CyA treatment was 12.3 months (range 2.6-55.0 months). Mean follow-up times were 3.7 years (range 1.2-12.9 years) from the beginning of the CyA treatment. Steroids were tapered off and stopped gradually after initiation of CyA. All patients responded to the CyA treatment within a mean of 1.8 months (range 1 week to 3.5 months). Twenty-three patients achieved stable remission with mean follow-up duration of 3.2 years and 6 patients seemed to become CyA-dependent, since they developed proteinuria when the treatment was stopped. Renal function was preserved in all patients but one who developed end-stage renal disease after poor compliance with CyA. We concluded that CyA treatment for HSN showing nephrotic-range proteinuria is very effective and a safe method, although some patients become CyA-dependent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21184240     DOI: 10.1007/s00467-010-1723-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  22 in total

1.  Cyclosporine A for heavy proteinuria in a child with Henoch-Schönlein purpura nephritis.

Authors:  Tomonosuke Someya; Kazunari Kaneko; Shuichiro Fujinaga; Risako Ohtaki; Mayako Hira; Yuichiro Yamashiro
Journal:  Pediatr Int       Date:  2004-02       Impact factor: 1.524

2.  Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low dose ciclosporine-A for 2 years for steroid-dependent nephrotic syndrome.

Authors:  K Kano; K Kyo; Y Yamada; S Ito; T Ando; O Arisaka
Journal:  Clin Nephrol       Date:  1999-07       Impact factor: 0.975

3.  Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis.

Authors:  Hiroshi Tanaka; Koichi Suzuki; Tohru Nakahata; Etsuro Ito; Shinobu Waga
Journal:  Pediatr Nephrol       Date:  2003-03-28       Impact factor: 3.714

4.  Long-term clinical and pathological effects of cyclosporin in children with nephrosis.

Authors:  M G Seikaly; H Prashner; B Nolde-Hurlbert; R Browne
Journal:  Pediatr Nephrol       Date:  2000-03       Impact factor: 3.714

5.  The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study.

Authors:  Jaana Ronkainen; Matti Nuutinen; Olli Koskimies
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

6.  Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis.

Authors:  R Habib; P Niaudet
Journal:  Clin Nephrol       Date:  1994-09       Impact factor: 0.975

7.  Henoch-Schönlein nephritis: long-term prognosis of unselected patients.

Authors:  O Koskimies; S Mir; J Rapola; J Vilska
Journal:  Arch Dis Child       Date:  1981-06       Impact factor: 3.791

8.  Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria.

Authors:  J Ronkainen; M Ala-Houhala; N P Huttunen; T Jahnukainen; O Koskimies; T Ormälä; M Nuutinen
Journal:  Clin Nephrol       Date:  2003-08       Impact factor: 0.975

9.  Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide.

Authors:  Penina Tarshish; Jay Bernstein; Chester M Edelmann
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

10.  Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis.

Authors:  Jaana Ronkainen; Helena Autio-Harmainen; Matti Nuutinen
Journal:  Pediatr Nephrol       Date:  2003-08-19       Impact factor: 3.714

View more
  18 in total

1.  Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring.

Authors:  Agnes Hackl; Jan U Becker; Lisa M Körner; Rasmus Ehren; Sandra Habbig; Eva Nüsken; Kai-Dietrich Nüsken; Kathrin Ebner; Max C Liebau; Carsten Müller; Martin Pohl; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2017-11-25       Impact factor: 3.714

2.  Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial.

Authors:  Outi Jauhola; Jaana Ronkainen; Helena Autio-Harmainen; Olli Koskimies; Marja Ala-Houhala; Pekka Arikoski; Tuula Hölttä; Timo Jahnukainen; Jukka Rajantie; Timo Ormälä; Matti Nuutinen
Journal:  Pediatr Nephrol       Date:  2011-05-28       Impact factor: 3.714

Review 3.  Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics.

Authors:  Guo-Xiang Hao; Lin-Lin Song; Dong-Feng Zhang; Le-Qun Su; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-01-14       Impact factor: 4.335

4.  Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil.

Authors:  Yue Du; Ling Hou; Chengguang Zhao; Mei Han; Yubin Wu
Journal:  Pediatr Nephrol       Date:  2011-11-13       Impact factor: 3.714

Review 5.  Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management.

Authors:  Jun-Yi Chen; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2014-12-29       Impact factor: 2.764

6.  Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study.

Authors:  Mikael Koskela; Timo Jahnukainen; Kira Endén; Pekka Arikoski; Janne Kataja; Matti Nuutinen; Elisa Ylinen
Journal:  Pediatr Nephrol       Date:  2019-04-06       Impact factor: 3.714

7.  Timely and individualized use of immunosuppression is associated with favourable outcomes in paediatric IgA vasculitis nephritis.

Authors:  Matthew Hon-Lam Lee; Eugene Yu-Hin Chan; Alison Lap-Tak Ma
Journal:  Pediatr Nephrol       Date:  2022-01-10       Impact factor: 3.651

Review 8.  Urological Manifestations of Henoch-Schonlein Purpura: A Review.

Authors:  Amanda Dalpiaz; Richard Schwamb; Yimei Miao; Jacquelyn Gonka; Wayne Walzter; Sardar A Khan
Journal:  Curr Urol       Date:  2015-07-10

Review 9.  Management of Small Vessel Vasculitides.

Authors:  Giuseppe Lopalco; Donato Rigante; Vincenzo Venerito; Giacomo Emmi; Maria Grazia Anelli; Giovanni Lapadula; Florenzo Iannone; Luca Cantarini
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

10.  Efficacy of triptolide for children with moderately severe Henoch-Schönlein purpura nephritis presenting with nephrotic range proteinuria: a prospective and controlled study in China.

Authors:  Li Wu; Jianhua Mao; Xia Jin; Haidong Fu; Huijun Shen; Jingjing Wang; Aimin Liu; Qiang Shu; Lizhong Du
Journal:  Biomed Res Int       Date:  2013-12-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.